Li Zhang

Dr. Li Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YZYujie Zhang
Yujie Zhang
YZYuxin Zhang
Yuxin Zhang
LZLi Zhang
Li Zhang
Esophageal cancer is a common disease in China with low survival rate due to no obvious early symptoms and lack of effective screening strategies. Traditional treatments usually do not produce desirable results in patients with advanced esophageal cancer, so immunotherapy which relies on tumor-related antigens is needed to combat low survival rates effectively. Cancer–testis antigens (CTA), a large family of tumor-related antigens, have a strong in vivo immunogenicity and tumor-restricted expressing patterns in normal adult tissues. These two characteristics are ideal features of anticancer immunotherapy targets and, therefore, promoted the development of some studies of CTA-based therapy. To provide ideas for the role of the cancer–testis antigens MAGE-A, NY-ESO-1, LAGE-1, and TTK in esophageal cancer, we summarized their expression, prognostic value, and development in immunotherapy.

28 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
YZYujie Zhang
Yujie Zhang
YZYuxin Zhang
Yuxin Zhang
LPLin Peng Peng
Lin Peng Peng
LZLi Zhang
Li Zhang
Esophageal cancer is one of the malignant tumors with poor prognosis in China. Currently, the treatment of esophageal cancer is still based on surgery, especially in early and mid-stage patients, to achieve the goal of radical cure. However, esophageal cancer is a kind of tumor with a high risk of recurrence and metastasis, and locoregional recurrence and distant metastasis are the leading causes of death after surgery. Although multimodal comprehensive treatment has advanced in recent years, the prediction, prevention and treatment of postoperative recurrence and metastasis of esophageal cancer are still unsatisfactory. How to reduce recurrence and metastasis in patients after surgery remains an urgent problem to be solved. Given the clinical demand for early detection of postoperative recurrence of esophageal cancer, clinical and basic research aiming to meet this demand has been a hot topic, and progress has been observed in recent years. Therefore, this article reviews the research progress on the factors that influence and predict postoperative recurrence of esophageal cancer, hoping to provide new research directions and treatment strategies for clinical practice.

26 September 2024 in eClinicalMedicine
Verified
Journal Article
Open access
YZYue Zhou
Yue Zhou
LPLin Peng
Lin Peng
FLFei Liang
Fei Liang
LCLi Chu
Li Chu
XCXiao Chu
Xiao Chu
ZZZhengfei Zhu
Zhengfei Zhu
Prospective data is limited on the efficacy and safety of consolidative stereotactic radiotherapy (SRT) in metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients harboring oligo-residual disease (ORD) after first-line third-generation EGFR-tyrosine kinase inhibitors (TKIs). In this single-arm, phase II trial, 61 patients from two academic centers were enrolled from March 2021 to March 2023. All these patients had metastatic EGFR-mutant NSCLC and harbored ORD after first-line third-generation EGFR-TKIs. Consolidative SRT was performed and EGFR-TKIs were not held during SRT. The primary endpoint was progression-free survival (PFS) and the secondary endpoints included overall survival and treatment-related adverse events (TRAEs). A prespecified propensity score matched (PSM) comparison was conducted with a contemporary cohort of patients who developed ORD but received EGFR-TKIs alone. This trial was registered with ClinicalTrails.gov, NCT04764214. All patients received consolidative SRT. With a median follow-up of 21.1 months, the median PFS was 29.9 (80% CI 22.4–32.4) months and the lower boundary exceeded the predefined threshold, meeting the primary endpoint. TRAEs occurred in 43 (70%) patients, with pneumonitis (27.9%) and esophagitis (26.2%) being the most common toxicities. Four patients (6.6%) reported grade ≥3 TRAEs, each for pneumonitis, esophagitis, leukopenia, and cranial radiation necrosis. PSM analysis showed significantly prolonged PFS in EGFR-TKI + SRT group compared to EGFR-TKI group (HR 0.46, 80% CI 0.20–0.61; p = 0.002). Consolidative SRT is associated with an encouraging PFS in first-line third-generation EGFR-TKI-treated metastatic NSCLC patients harboring ORD, with generally acceptable toxicities. Further confirmatory studies are warranted. Hui Lan Public Welfare and the Chinese Society of Clinical Oncology Foundation.

1 February 2021 in Cancer Letters
Verified
Journal Article
Closed access
JYJupeng Yuan
Jupeng Yuan
HXHuaixin Xing
Huaixin Xing
YLYankang Li
Yankang Li
YSYemei Song
Yemei Song
NZNasha Zhang
Nasha Zhang
MYMing Yang
Ming Yang

4 November 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SLShiyu Li
Shiyu Li
SZShuangli Zhu
Shuangli Zhu
HWHongqu Wei
Hongqu Wei
PZPengfei Zhu
Pengfei Zhu
YJYing Jiao
Ying Jiao
LZLi Zhang
Li Zhang
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant benefits to non-small cell lung cancer patients with EGFR mutations, which represent a breakthrough in lung cancer therapy. However, patients will ultimately develop the acquired resistance to the first- or second-generation EGFR-TKIs after a period of treatment, and EGFR T790M mutation is the most common resistant mechanism. The third-generation EGFR-TKIs target T790M mutation and show potent anti-tumor efficacy, especially in central neural system response. Unfortunately, patients inevitably get resistant to the third-generation EGFR-TKIs due to various mechanisms, which can be mainly divided into EGFR-dependent and -independent ones. EGFR-dependent mechanism refers to manifold EGFR mutations while EGFR-independent mechanisms include bypass signal activation, histologic transformation and so on. To precisely address this issue and improve clinical outcomes, various other therapies (e.g. chemotherapy, radiotherapy, etc.) in combination with the third-generation EGFR-TKIs are designed. However, the current results of combination therapies are insufficient and ambiguous, which remain further exploration. Herein, we provide an updated landscape of the third-generation EGFR-TKIs and elaborate on the complex resistant mechanisms. Notably, we summarize the combination therapies with third-generation EGFR-TKIs and discuss their limitations and future perspective, aiming at providing insights to clinicians from bench to bedside.

1 February 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JTJianbo Tian
Jianbo Tian
MZMing Zhang
Ming Zhang
MJMeng Jin
Meng Jin
FZFengqin Zhang
Fengqin Zhang
QCQian Chu
Qian Chu
HZHuilan Zhang
Huilan Zhang
The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely repurposed as a treatment of severely ill patients without robust evidence supporting its use. In this study, we aimed to systematically describe the effectiveness of treatment and prevention of the cytokine storms in COVID-19 patients with tocilizumab. In this multicentered retrospective and observational cohort study, 65 patients with COVID-19 receiving tocilizumab and 130 not receiving tocilizumab were propensity score matched at a ratio of 2:1 based on age, sex, and comorbidities from January 20, 2020 to March 18, 2020 in Wuhan, China. After adjusting for confounding, the detected risk for in-hospital death was lower in the tocilizumab group versus nontocilizumab group (hazard ratio = 0.47; 95% confidence interval = 0.25–0.90; p = 0.023). Moreover, use of tocilizumab was associated with a lower risk of acute respiratory distress syndrome (odds ratio = 0.23; 95% confidence interval = 0.11–0.45; p < 0.0001). Furthermore, patients had heightened inflammation and more dysregulated immune cells before treatment, which might aggravate disease progression. After tocilizumab administration, abnormally elevated IL-6, C-reactive protein, fibrinogen, and activated partial thromboplastin time decreased. Tocilizumab may be of value in prolonging survival in patients with severe COVID-19, which provided a novel strategy for COVID-19–induced cytokine release syndrome. Our findings could inform bedside decisions until data from randomized, controlled clinical trials become available. Key Points Tocilizumab could prolong survival among hospitalized patients with severe COVID-19. Tocilizumab weakens the inflammatory response while sustaining immune responses. During the tocilizumab treatment, no severe adverse drug reactions were reported.